Suppr超能文献

司来吉兰作为早期帕金森病初始单药治疗的作用。

Role of selegiline as initial monotherapy in early Parkinson's disease.

作者信息

Bhatia M, Jain S, Maheshwari M C

机构信息

Department of Neurology, Neurosciences Centre AIIMS New Delhi.

出版信息

J Assoc Physicians India. 1994 Jan;42(1):30-2.

PMID:7836244
Abstract

Twenty patients of Idiopathic Prakinson's disease in the early phase were enrolled to study the efficacy and safety of selegiline as monotherapy. The mean duration of time before levodopa had to be initiated was 9.75 months. The UPDRS scores for activities of daily living, motor examination, tremor and total score showed significant improvement initially with subsequent worsening. Selegiline was well tolerated and there were no serious side-effects. In conclusion, selegiline may have a short lasting symptomatic effect in IPD and is well tolerated.

摘要

20例早期特发性帕金森病患者入选,以研究司来吉兰作为单一疗法的疗效和安全性。在必须开始使用左旋多巴之前的平均时间为9.75个月。日常生活活动、运动检查、震颤和总分的统一帕金森病评定量表(UPDRS)评分最初显示有显著改善,随后恶化。司来吉兰耐受性良好,没有严重副作用。总之,司来吉兰在特发性帕金森病中可能有短期的症状性疗效,且耐受性良好。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验